Kriya Therapeutics raises $313.3 funding

(Image credit: ©Hand Robot/AdobeStock)

Kriya Therapeutics reported in an SEC filing it has raised $313.3 million in a recent funding round.¹

The filing does not detail fund specificity or funding sources but rather only states two investors participated in the funding push. This $313.3 million adds to the company’s $100 million Series B raise in July 2021 and $270 million Series C round in May 2022, which was then extended by $150 million in July 2023.¹

The gene therapy company is focused on advancing a pipeline of single-dose gene therapy treatments for a variety of chronic conditions such as geographic atrophy secondary to age-related macular degeneration (AMD), trigeminal neuralgia, thyroid eye disease and focal epilepsy, as well as metabolic diseases such as type 1 diabetes and metabolic dysfunction-associated steatohepatitis (MASH).

Kriya’s most advanced asset is KRIYA-825. An adeno-associated virus (AAV)-based gene therapy, KRIYA-825 expresses a complement CR2-CR1 fusion protein—designed to inhibit the activity of complement C3 and C5—for the treatment of GA. It expresses a protein that disrupts the complement cascade, which have been implicated in the development and progression of GA.2

Earlier this year, the company announced preclinical data on KRIYA-825.

The data were presented by Kriya in a presentation titled “A Novel AAV Gene Therapy Complement Inhibitor: KRIYA-825 Exhibits Dose-Dependent Murine Efficacy and NHP Biodistribution” at the 2025 Association for Research and Ophthalmology (ARVO) annual meeting held May 4-8 in Salt Lake City. Visit Modern Retina for the highlights.²

Kriya’s KRIYA-825 was designed with the following goals in mind:²

• Robust complement inhibition: a complement receptor 2-complement receptor 1 (CR2-CR1) fusion protein—where the CR1 domain is designed to block the activity of both complements C3 and C5, while the CR2 domain is designed to bind to the surfaces of cells where complement fragments deposit and cause damage.
• Multi-year durability: AAV-medicated continuous expression of CR2-CR1 fusion protein following a 1-time injection to eliminate the need for frequent intravitreal injections that currently available therapies for GA require.
• Targeted delivery: A 1-time suprachoroidal injection to achieve transduction of, and the delivery of therapeutic protein to, retinal cells while minimizing inflammation and overall patient burden.

“We are excited about the tremendous potential of KRIYA-825 for the treatment of geographic atrophy,” said Shankar Ramaswamy, MD, cofounder and CEO of Kriya.²

“We are proud of the data that the team has generated to date, and we look forward to continuing to share further updates as we advance KRIYA-825 through clinical development for patients with geographic atrophy.”

According to previous reporting on Modern Retina,² and in the most recent press release,¹ KRIYA-825 has not yet been approved for use by the US Food and Drug Administration, and the clinical safety and efficacy of KRIYA-825 for the treatment of GA has not yet been established. At the time of this article, KRIYA-825 has cleared IND-enabling studies and is poised to enter clinical testing for GA.¹

The company is also developing KRIYA-748, a gene therapy that expresses an engineered ion channel that can cut the rate and severity of pain attacks in patients with trigeminal neuralgia.

After receiving the recent funding amount, Kriya ranks among the top funding rounds in biopharma this year. The company follows Isomorphic Labs, which brought in $600 million in March, as well as Verdiva Bio and Pathos AI, which brought in $411 million in January and $365 million in February, respectively. Kriya falls just below Eikon Therapeutics, which raised $351 million in February.

Reference:

1. Gene Therapy Specialist Kriya Raises $313M. BioSpace. Published August 18, 2025. Accessed August 21, 2025. https://www.biospace.com/business/gene-therapy-specialist-kriya-raises-313m

2. Filkins K. KRIYA-825 gene therapy data announced. Modern Retina. Published May 19, 2025. Accessed August 21, 2025. https://www.modernretina.com/view/kriya-825-gene-therapy-data-announced